Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers.* Dexcom Smart Basal is FDA cleared and now the ...
What Is Awiqli, and Why Does It Matter? Awiqli (insulin icodec-abae) is a once-weekly long-acting basal insulin injection approved by the FDA for adults with type 2 diabetes. It helps lower blood ...
Dr. Marie McDonnell, the director of the Brigham Diabetes Program at Brigham and Women’s Hospital in Boston, told TODAY that basal insulin is a long-acting insulin therapy that helps the body process ...
COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment (insulin glargine U100 and insulin aspart) in ...
The MarketWatch News Department was not involved in the creation of this content. -- Awiqli(R) (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDA1 -- ...
PLAINSBORO, N.J., March 26, 2026 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the ...
Awiqli (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDA Awiqli offers adults with type 2 diabetes an alternative to daily basal insulin injections, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results